Bristol-Myers, Daiichi Sankyo to test Opdivo combo for cancers

(Reuters) - Bristol-Myers Squibb Co and Daiichi Sankyo said they were evaluating a combination of Bristol-Myers' immuno-oncology drug, Opdivo, with the Japanese company's experimental drug in patients with breast and bladder cancers.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news